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Abstract
Crimean-Congo Hemorrhagic Fever (CCHF) is a life threatening acute viral infection char-
acterized by fever, bleeding, leukopenia and thrombocytopenia. It is a major emerging infec-
tious diseases threat, but its pathogenesis remains poorly understood and few data exist for
the role of apoptosis in acute infection. We aimed to assess apoptotic gene expression in
leukocytes in a cross-sectional cohort study of adults with CCHF. Twenty participants with
CCHF and 10 healthy controls were recruited at a tertiary CCHF unit in Turkey; at admission
baseline blood tests were collected and total RNA was isolated. The RealTime ready
Human Apoptosis Panel was used for real-time PCR, detecting differences in gene expres-
sion. Participants had CCHF severity grading scores (SGS) with low risk score (10 out of
20) and intermediate or high risk scores (10 out of 20) for mortality. Five of 20 participants
had a fatal outcome. Gene expression analysis showed modulation of pro-apoptotic and
anti-apoptotic genes that facilitate apoptosis in the CCHF patient group. Dominant extrinsic
pathway activation, mostly related with TNF family members was observed. Severe and
fatal cases suggest additional intrinsic pathway activation. The clinical significance of rela-
tive gene expression is not clear, and larger longitudinal studies with simultaneous mea-
surement of host and viral factors are recommended.
Introduction
Crimean Congo Hemorrhagic Fever (CCHF) is a life threatening acute viral infection caused
by a RNA virus belonging to the family Bunyaviridae. The first documented infection was
observed in 1944 in the Crimea region of Ukraine and was designated as Crimean haemorrha-
gic fever. It was later observed in Congo in 1956 and the name was changed to CCHF [1].
CCHF virus (CCHFV) is an enveloped single-stranded RNA virus, the genome of which
includes small (S), medium (M) and large (L) segments, and phylogenetic analysis of CCHFV
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strains has revealed high degree of genetic diversity amongst strains, particularly between
viruses from different geographic regions [2].
CCHF is a major emerging infectious disease threat and is widely distributed across Africa,
Eastern Europe, Asia and the Middle East. Turkey reports up to 1000 cases per year and
CCHFV is predominantly transmitted to humans via Hyalomma spp. ticks [3]. Clinical fea-
tures of disease represent a spectrum of disease severity, characterized by fever, bleeding and
lethargy, and has a case fatality rate of 5–50%. The most common hematologic findings in
CCHF are leukopenia (60%) and thrombocytopenia (100%)[4], with evidence of haemophago-
cytosis in the bone marrow [5]. At present there is no approved vaccine or therapeutic agent,
although ribavirin and hyper immune serum are utilized by some clinicians.
The pathogenesis of CCHF remains poorly understood but apoptotic programmed cell
death has been proposed to play a role [2]. Regulation of apoptosis through suppression or
induction during acute viral infection is important for virus survival and dissemination [6].
Apoptosis can be started by an extrinsic (death receptor mediated) or intrinsic pathway (mito-
chondria mediated). The external pathway is activated when ligands—TNF-α, TNF-related
apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL) known as CD95L, bind to death
receptors on the cell surface. Some TRAIL receptors do not contain death domains and are
referred to as decoy receptors 1 (DcR1) (TNFRSF10C) and 2 (DcR2) (TNFRSF10D) and pre-
vent apoptosis signals from initiating. The intrinsic pathway to cell death is controlled by inter-
actions on the mitochondrial outer membrane between sub-groups of the BCL-2 family,
including the effector proteins BAX and BAK [7]. Both pathways ultimately result in up-regu-
lation of effector caspases (caspase-3 & caspase-7) resulting in fragmentation of the DNA, cyto-
skeleton, nuclear proteins and expression of ligands for phagocytic cells [8].
Apoptosis has been demonstrated in a range of cells in other acute viral infections including
Dengue [9]. Massive intravascular apoptosis, including leukocyte apoptosis, has also been dem-
onstrated in Ebola virus infection [10], where it has been shown to be associated with a fatal
outcome. CCHFV has been shown to induce caspase-3 and modulate both intrinsic and extrin-
sic pathways in cell cultures [11,12]. Elevated apoptotic markers have also recently been dem-
onstrated in a paediatric cohort of CCHF [13], and associations were found with the disease’s
severity criteria. We have previously observed apoptotic transformation in leukocytes in
peripheral blood smears of patients with CCHF, and in the present work, this was investigated
further by studying up and down-regulation of genes which are involved in leukocyte apoptosis
in a cohort of adult patients with CCHF.
Methods
Study Participants
Participants in the study were recruited from a designated CCHF tertiary referral hospital in
Turkey between May and August 2011. Hospitalized patients with suspected CCHF and
healthy controls were recruited into the study with CCHF confirmed through viral nucleic acid
detection by polymerase chain reaction (PCR) of plasma in the Ministry of Health regional ref-
erence laboratory in Samsun. Patients with a negative PCR result were excluded from further
analysis. All participants were free from antiviral drugs and immunotherapy for CCHF during
blood sampling. Demographic, epidemiological and clinical data were systematically extracted
from the medical records of all participants with confirmed CCHF. Participants had a CCHF
severity grading score (SGS) performed in accordance with Bakir et al [14] at admission, and
were classified into three risk groups for mortality: low (0–4 points), intermediate (5–8 points),
and high (9–14 points) (S1 and S2 Tables). The CCHF SGS was established using several clini-
cal and laboratory variables that were assumed to be associated with mortality and had clinical
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importance. It has subsequently been validated and may be used to aid triage/risk stratification
of patients and to improve the functionality of healthcare staff.
Patient sampling and RealTime ready Apoptosis Panel
Four milliliter blood samples were drawn into EDTA blood tubes on the first day of hospitali-
zation and standard baseline blood tests took place (Table 1). Red Blood Cell Lysis Buffer
(Roche Diagnostics, Germany) was added to the blood samples and total RNA was isolated uti-
lizing a High Pure RNA Isolation Kit (Roche Diagnostics, Germany). RNA samples were then
stored at kept at -70°C until sample processing when cDNAs was obtained using a Transcriptor
First Strand cDNA Synthesis Kit (Roche Diagnostics, Germany). Expression levels of apopto-
tic-related genes were determined using The RealTime ready Human Apoptosis Panel (Roche
Diagnostics, Germany) and a LightCycler 480 Probes Master. The RealTime ready Apoptosis
Panel consists of ready-to-use qPCR assays designed for expression profiling of genes involved
in the apoptosis pathway. Each multi-well plate contains assays for 84 different apoptosis-
related genes and seven housekeeping genes, as well as five controls. This study was approved
by the Ondokuz Mayis University Ethical Committee (2010/178) and all patients provided
written informed consent.
Statistical analyses
The REST 2009 program (Qiagen, Germany) was used to quantify changes in the expression
levels of genes and to determine statistical differences between the CCHF and control groups,
and between CCHF fatal and survivor groups. Differences in gene expression were also ana-
lyzed between intermediate or high SGS risk score participants (Group 1) and low SGS risk
score (Group 2). P values less than or equal to 0.05 were accepted as statistically significant.
Descriptive analysis of patient characteristics was performed using the Statistical Package for
the Social Sciences (SPSS) version 15 for Windows (SPSS Inc., Chicago, IL, USA).
Table 1. Participant laboratory characteristics according to severity score: Mean (Minimum-Maximum) ±Standard Deviation.
Variable (reference range) units Low risk (n = 10) Intermediate risk (n = 8) High risk (n = 2)
Age years 50.4 (39–63)±8 56.8 (20–73)±21 67 (63–71)±6
Blood Urea Nitrogen (5–24) mg/dL 14.3 (8.6–24)±5 21 (6.5–44)±12 40.5 (30–51.4)±15
Creatinine (0.4–1.4) mg/dL 0.85 (0.55–1.04) ±0.2 1.1 (0.53–1.9) ±0.4 1.82 (1.81–1.84) ±0.02
Lactic dehydrogenase (LDH) (140–280) IU/L 370 (183–567) ±132 1731 (705–5067) ±1446 3122 (2447–3797) ±955
Aspartate transaminase (AST) (5–40) IU/L 119 (16.4–279) ±83 722 (128–2198) ±674 1299 (1087–1511) ±300
Alanine transaminase (ALT) (7–56) IU/L 66 (16–209) ±57 237 (24–547) ±177 501 (406–596) ±134
Hemoglobin(12–15) gr/dL 14 (11.3–15.6) ±1.3 14.5 (12.2–18.3) ±2 11.6 (9–14.2) ±4
Platelet count (150–450) x109 cells/L 103 (52–212) ±54 25.6(12–52) ±16 21 (10–32) ±16
PT(11–14) seconds 11.9 (10.8–12.9) ±0.8 14 (10.2–17.4) ±2 22.65 (13.3–32) ±13
PTT (25–35) seconds 35.5 (27–43) ±6 55 (31.3–72.4) ±14 84.5 (77–92) ±11
International normalized ratio (INR) 1.05 (0.96–1.16) ±0.10 1.3 (0.91–1.57) ±0.20 2.08 (1.19–2.96) ±1.0
Leucocyte (3.9–11.7) x109/L 2.39 (0.94–5.00) ±1.18 5.73 (1.89–9.89) ±3.19 10.91(7.74–14.08) ±4.48
Neutrophil (1.9–7.9) x109/L 1.61(0.59–3.00) ±0.76 4.51 (1.53–8.50) ±2.68 7.92 (6.24–9.60) ±2.38
Lymphocyte(1.3–3.6) x109/L 0.571 (0.27–1.59) ±0.38 0.80 (0.30–1.83) ±0.58 2.26(0.88–3.63) ±1.95
Monocyte (0.2–0.5)x109/L 0.11 (0.20–0.24) ±0.08 0.135(0.07–0.22) ±0.06 0.28 (0.15–0.41) ±0.18
Basophil(0–0.1) x109/L 0.02(0.01–0.07) ±0.02 0.01(0.02–0.03) ±0.01 0.062 (0.02–0.10) ±0.06
Eosinophil (0–0.4)x109/L 0.03 (0.01–0.06) ±0.02 0.012(0.01–0.04) ±0.01 0.02(0.02–0.02) ±0.02
doi:10.1371/journal.pone.0157247.t001
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Results
Twenty patients (female: 6; male: 14) and 10 healthy controls (female: 5; male: 5) were included
in this study. The patients mean age was 54.6 (20–73) years-old. At admission, participants
were a mean 3.4 (1–6) days since onset of symptoms of disease. According to the SGS system
10 participants were low risk (score 0–4), 8 participants intermediate risk (5–8), and 2 partici-
pants in the high risk group (9–14). Five of the 20 participants (25%) died of CCHF during the
hospital admission. Three of the 5 fatal cases had an SGS score of 8, 1/5 a score of 9 and 1/5 a
score of 13. Petechiae and/or ecchymosis were detected in 7/20 (35%) participants, and signifi-
cant haemorrhage developed in a further 6/20 (30%) participants.
Detailed laboratory characteristics are displayed in Table 1 stratified by severity group.
Mean cohort data (n = 20) at baseline showed: leukocytes 4.58 x 109 cells/L (0.94–14.1); neutro-
phils 3.4 x 109 cells/L (0.59–9.6); lymphocytes 0.83 x 109 cells/L (0.03–3.63); monocytes 0.14
x109 cells/L (0.02–0.41); basophils 0.11 x109 cells/L (0.01–1.01); alanine aminotransferase
(ALT) 178 IU/L (16–596); aspartate transaminase (AST) IU/L 410 (16.4–2198); lactate dehy-
drogenase (LDH) 1233 IU/L (183–5067); platelets 69.7 x 109/L (10–212); prothrombin time
(PT) 13.8 seconds (10.2–32); partial thromboplastin time (PTT) 48.2 seconds (26.6–92); inter-
national normalized ratio (INR) 1.24 (0.91–2.96); blood urea nitrogen (BUN) 19.6 mg/dL (6.5–
51.4); and creatinine 1.05 mg/dL (0.53–1.9). The healthy control group exhibited a normal pro-
file in laboratory parameters.
Expression analysis showed that the BCL2L1, BCL2L2, BIRC5, CASP2, CASP3, SOCS2,
TNFSF10, and TRAF3 genes were up-regulated and the BCL2L10, BID, CFLAR, MCL1,
NFKB2, PTEN, STAT5B, TNFRSF10C, TNFRSF10D, TNFRSF1B, and TRAF1 genes were
down-regulated in the patient group compared with the healthy control group (Table 2).
There were no significant changes in the expression of AKT1, APAF1, AVEN, BAD, BAG1,
BAK1, BAX, BBC3, BCL2, BCL2L11, BCL2L13, BIK, BIRC2, BIRC3, BOK, CAD, CASP1,
Table 2. Changes in gene expression level (up- or down-regulation) in the patient group compared with the healthy group.
Gene Reaction Efﬁciency ExpressionTimes Std. Error Results 95% C.I. P-value
BCL2L1 1,0 2,125 0,850–6,082 UP 0,262–11,940 0,011
BCL2L10 1,0 0,128 0,012–3,619 DOWN 0,002–17,597 0,015
BCL2L2 1,0 3,373 1,947–9,525 UP 0,007–24,859 0,028
BID 1,0 0,251 0,117–0,866 DOWN 0,001–1,753 0,005
BIRC5 1,0 17,412 2,827–70,762 UP 1,224–110,335 0,000
CASP2 1,0 1,474 0,765–2,667 UP 0,404–6,175 0,047
CASP3 1,0 2,903 0,952–11,071 UP 0,028–32,494 0,028
CFLAR 1,0 0,468 0,207–1,012 DOWN 0,068–2,369 0,003
MCL1 1,0 0,336 0,127–0,817 DOWN 0,014–1,622 0,005
NFKB2 1,0 0,289 0,146–0,628 DOWN 0,037–0,990 0,000
PTEN 1,0 0,227 0,120–0,707 DOWN 0,000–1,492 0,009
SOCS2 1,0 6,069 1,772–19,478 UP 0,688–86,897 0,000
STAT5B 1,0 0,188 0,029–0,674 DOWN 0,002–1,168 0,006
TNFRSF10 C 1,0 0,047 0,012–0,262 DOWN 0,000–0,822 0,001
TNFRSF10 D 1,0 0,452 0,151–1,588 DOWN 0,063–4,274 0,035
TNFRSF1B 1,0 0,378 0,193–0,847 DOWN 0,065–1,706 0,001
TNFSF10 1,0 1,992 0,768–4,350 UP 0,247–22,329 0,039
TRAF1 1,0 0,440 0,128–1,319 DOWN 0,067–3,004 0,023
TRAF3 1,0 1,978 0,853–4,860 UP 0,287–20,458 0,027
doi:10.1371/journal.pone.0157247.t002
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CASP10, CASP4, CASP5, CASP6, CASP7, CASP8, CASP8AP2, CASP9, CRADD, DFFA, DIA-
BLO, endoG, FADD, FAM96A, FAM96B, FAS, FASLG, HMGB1, HRK, HSP90B1, HTRA2,
LRDD, NFKB1, NGFR, PMAIP1, REL, RELA, RELB, SOCS3, STAT1, STAT5A, TNF,
TNFRSF10 A, TNFRSF10 B, TNRFSF1A, TNFRSF25, TNFSF8, TP53, TP53I3, TRAF2, TRAF5,
TRAF6, and TRAF7 genes in the patient group compared with the healthy control group.
Changes in the expression of apoptosis-related genes between fatal and survivor group are
shown in Table 3. Three genes showed significant down-regulation in expression in fatal cases
compared to survivors (BBC3, BCL2L2 and CASP2), and one gene significant up-regulation
(TNFRSF1A).
Changes in the expression of apoptosis-related genes between the intermediate/high SGS
risk group and low SGS risk group participants are shown in Table 4. Expression analysis
showed that the BAX, BCL2L13, CASP4, CASP9, CRADD, ReIA, TNFRSF10C and TNFRSF1A
genes were up-regulated and the BCL2L10 and BCL2L11 genes were down-regulated.
Discussion
The pathogenesis of CCHF remains poorly understood despite significant recent scientific
progress and research efforts [2]. Viral factors and an impaired host immune response includ-
ing an exaggerated pro-inflammatory cytokine effect, all play a role in the severity and progno-
sis of viral haemorrhagic fevers including CCHF [15,16]. Direct cytopathic effects of the virus
contribute to disease severity, but the targeting of the innate immune response, combined with
a subsequent failure in adaptive immunity, exacerbated by lymphocyte apoptosis, play key
roles in pathogenesis and outcome [17]. In this study, we aimed to evaluate the role of apopto-
sis in CCHF, through expression and regulation of apoptotic genes in an adult cohort in Tur-
key. The cohort had an ideal balance of severe/fatal and moderate/mild CCHF cases to
investigate apoptotic change and a large panel of apoptotic genes from different pathways were
evaluated.
Table 3. Changes in gene expression level (up- or down-regulation) in fatal cases compared to survivors.
Gene Reaction Efﬁciency Expression times Std. Error Results 95% C.I. P-value
BBC3 1,0 0,423 0,137–1,093 DOWN 0,057–1,896 0,015
BCL2L2 1,0 0,121 0,002–0,862 DOWN 0,001–1,557 0,002
CASP2 1,0 0,546 0,325–0,916 DOWN 0,177–1,704 0,006
TNFRSF1A 1,0 3,681 0,909–17,450 UP 0,165–35,533 0,036
doi:10.1371/journal.pone.0157247.t003
Table 4. Changes in gene expression level (up- or down-regulation) in intermediate and high risk participants compared with low risk participants.
Gene Reaction Efﬁciency Expression times Std. Error Results 95% C.I. P-value
BAX 1,0 2,110 0,824–5,344 UP 0,340–14,112 0,027
BCL2L10 1,0 0,101 0,004–2,043 DOWN 0,001–26,704 0,030
BCL2L11 1,0 0,049 0,002–1,603 DOWN 0,000–28,436 0,013
BCL2L13 1,0 2,876 0,685–12,136 UP 0,215–44,091 0,033
CASP4 1,0 8,341 0,845–104,284 UP 0,036–611,645 0,024
CASP9 1,0 1,707 0,907–3,446 UP 0,465–6,325 0,030
CRADD 1,0 7,342 0,676–252,737 UP 0,273–1005,402 0,026
RelA 1,0 5,626 0,775–59,557 UP 0,085–130,134 0,018
TNFRSF10C 1,0 5,898 0,764–36,234 UP 0,150–2406,870 0,020
TNFRSF1A 1,0 3,984 1,077–17,458 UP 0,227–32,879 0,008
doi:10.1371/journal.pone.0157247.t004
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The gene of caspase-3, that is an important executioner caspase in apoptosis, was up-regu-
lated in our study compared to healthy volunteers. With respect to the extrinsic pathway, one
of its most important ligands TRAIL (TNF-related apoptosis inducing ligand), that induces
apoptosis, was up-regulated. Decoy receptors of TRAIL, DcR1 and DcR2 were down-regulated
resulting in cells being more sensitive to apoptosis [18]. Another important finding related to
cell sensitivity to apoptosis was the down-regulation of c-FLIP expression. The c-FLIP protein
structurally resembles caspase-8 and effects the extrinsic pathway in opposite ways dependent
on the extent of its expression. Down-regulated and low levels of c-FLIP are thought to pro-
mote caspase-8 activation, whereas in high concentrations c-FLIP may compete for binding,
reduce caspase-8 activity and the cell’s susceptibility to apoptosis [7,19].
Analysis of the intrinsic apoptotic pathway related genes, showed up-regulation of anti-apo-
ptotic BIRC5 [20] (an inhibitor of apoptosis protein) and BID, a pro-apoptotic member of the
Bcl-2 family was down-regulated compared to controls. Protein kinase B (AKT) plays a key
role in cell survival including inhibition of apoptosis and cell proliferation. Phosphatase and
tensin homolog (PTEN) which is a critical regulator of AKT [21] was also found to be down-
regulated. No significant differences in gene expression were noted in BAX or DIABLO genes,
which are important components of the intrinsic pathway. These findings combined with
BIRC5, PTEN and BID results do not support major intrinsic apoptotic pathway activation in
CCHF patients compared to controls and the up-regulation demonstrated in caspase-2 may be
independent [22].
NF-κB is a major rapidly acting transcription factor that regulates genes responsible for
both the innate and adaptive immune response, including apoptotic genes affecting both the
intrinsic and extrinsic pathways [23]. NFκB exerts its anti-apoptotic effect via two pathways,
the canonical and non-canonical that both result in mature dimeric NFκB proteins that trans-
locate to the cell nucleus and activate anti-apoptotic genes. The NFκB system is composed of
five subunits, which are RelA, RelB, c-Rel, p50 monomer (encoded by the NFκB1 gene) and
p52 monomer (encoded by the NFκB2 gene) [24]. While the p50: RelA, NFκB dimer is domi-
nant in canonical pathway, the p52: RelB, NFκB dimer is dominant in non-canonical pathway.
There was significant down-regulation in NFκB2 gene expression whilst there were no
changes observed for RelA, RelB, c-Rel, and p50. We interpreted this result as inhibition of the
non-canonical NFκB pathway because of down regulation of its dominant member NFκB2.
These finding are also consistent with our results as the canonical pathway is also thought to be
predominantly involved in the regulatory process of the intrinsic apoptotic pathway [23].
Interactions also exist between NFκB and c-FLIP and the transcription of c-FLIP is positively
regulated by NFκB. NFκB levels are also increased by the interaction of c-FLIP with the TRAF-
1 (TNF receptor-associated factor-1) and TRAF-2 [25,26]. TRAF-1 expression was found to be
down-regulated in our study and TRAF 3, that has a critical negative regulatory role in non-
canonical NFκB signaling [24,27], was up-regulated.
The JAK (Janus tyrosine kinase)-STAT (Signal Transducer and Activator of Transcription)
pathway is an important cell signaling cascade that is activated by cytokines and their recep-
tors. Activation of STAT initiates synthesis of SOCS (suppressors of cytokine signaling) nega-
tively regulates STAT signaling by serving as a negative feedback loop [28]. Compared to
healthy controls STAT5B gene expression was down-regulated in CCHF combined with up-
regulation of SOCS2, indicating a direct cytokine effect. As previously discussed, the up-regu-
lated TRAIL and TRAF-3 and down-regulated TRAF-1, DcR1 and DcR2, all belong to the TNF
family and are implicated in apoptosis in CCHF. Its receptor, TNFRSF1B that also serves as an
inhibitor of TNF-related apoptosis [29,30], was also found to be down-regulated in our study.
The role of pro-inflammatory cytokines and a ‘cytokine storm’ in CCHF disease severity are
increasingly recognized, with TNF-α expression linked to clinical severity and mortality [16].
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Our results support this hypothesis suggesting additional effects through cytokine mediated
apoptosis.
Previous research has implicated important clinical and laboratory factors that are related
to mortality in CCHF [31]. As a result, as well comparing gene expression in CCHF and
healthy volunteers acting as controls, we wanted to evaluate the differences further through
sub-group analysis of fatal and non-fatal CCHF cases and by stratifying for CCHF disease
severity. There were fewer significant differences but TNFRSF1A (TNF receptor superfamily
member 1A) was up-regulated in the fatal CCHF group. This receptor has a key role in TNF-
related apoptosis [21,22]. PUMA (p53 up-regulated modulator of apoptosis), also known as
BBC3 (BCL-2 binding component), was down-regulated and the down-regulation of caspase-2
gene expression in the fatal group may be related to p53 [32]. BCL-2 is a regulatory protein
that may induce or inhibit apoptosis and Baize et al. elicited interesting results when evaluating
BCL-2 levels in Ebola virus infection. Increased synthesis of BCL-2 mRNA was detected at the
time of T-cell activation in survivors in their study, with disappearance of BCL-2 mRNA
expression observed in fatal cases [10].
In our study, there was no difference between BCL-2 gene expression between fatal and
non-fatal cases. However, BCL2L2 which is another anti-apoptotic protein was down-regulated
in the fatal CCHF group compared to survivor group. In contrast it was up-regulated in the
larger cohort when compared to the healthy volunteers. BLC2L2 (also known as BCL-W) is
one of the pro-survival proteins of the BCL-2 family and these contrasting results, in combina-
tion with the down-regulation of PUMA, suggest modulation of the intrinsic pathway in fatal
cases, and are interesting targets for further research. Intrinsic pathway activation linked to
CCHF disease severity was also suggested by gene expression analysis of the intermediate/high
SGS risk group compared to the low SGS risk group. There was up-regulation of pro-apoptotic
BAX, BCL2L13, CASP 9 and down-regulation of anti-apoptotic BCL2L10 (that suppresses apo-
ptosis) in the intermediate and high risk groups. CRADD which acts with caspase-2 in intrinsic
pathway activation [33] was found up-regulated. In the intermediate/high risk CCHF group
there was also evidence of extrinsic pathway activation, with upregulated caspase-4, that has a
role in apoptosis induced by TRAIL [34], and up-regulation of the pro-apoptotic TNFRSF1A
gene, and decoy receptor TNFRSF10C gene.
To our knowledge, this is the first in vivo study to describe the apoptotic gene expression in
leukocyte in CCHF and supports our previous observations in CCHF patients. Leukocyte apo-
ptosis may be responsible for the cytopenia observed in CCHF, and apoptotic signals will also
most likely affect myeloid cells in bone marrow. During apoptosis, cells express ligands for
phagocytic cells and trigger phagocytosis, and the observed haemophagocytosis in bone mar-
row may be a further clue to apoptosis in the bone marrow in CCHF. Apoptotic processes may
also be more widespread targeting liver, brain and endothelial cells [35], and the multi-organ
failure seen in CCHF may be as a result of haemophagocytic activity triggered by apoptosis in
several organs. One of the limitations of the study is that we did not evaluate apoptotic gene
expression individually by leukocyte subtypes. Given the heterogeneous nature of the clinical
disease a larger sample size, particularly in the fatal and survivor group would have increased
the studies power to detect differences. In addition, we utilized the SGS tool for grading severity
of CCHF and in subsequent analysis by group. Although this has been validated as a useful
prognostic tool it is clear that SGS has its own limitations, relates to a specific disease time-
point and could be improved and refined incorporating variables such as CCHFv viral load.
We also only report cross-sectional gene expression data at one time-point during an early
stage of CCHF clinical disease. A longitudinal study design with additional sampling points
would have provided important additional data, and in the future novel methods such as high
resolution sequencing will provide further insights. This must be balanced against the practical
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difficulties and laboratory safety requirements of undertaking research in patients with viral
haemorrhagic fever.
It must also be recognized that although the values we have reported may be statistically sig-
nificant, the clinical significance of the relative expression of particular genes is not clear. A
2-fold increase in expression may be a very important change for some genes and relatively
insignificant for others, regardless of statistical significance. Although we have investigated our
results linked to patient outcomes and CCHF severity grading score (SGS), these are broad
measures highlighted by the fatal cases that occurred in the intermediate group. It must also be
appreciated that as per the clinical disease in CCHF there is probably a spectrum of apoptosis
in CCHF dependent on disease stage and disease severity. Improved understanding of apopto-
tic processes in CCHF could be achieved through simultaneous measurement of host and viral
factors including cytokine response, quantitative viral load and in depth genomic sequencing
in cohorts with a standardized platform of supportive care.
Further research is also required to determine the broader role of apoptosis in the pathogen-
esis of acute viral infection and CCHF. In particular research to improve the understanding of
the specific viral and host immune response factors that initiate apoptotic signaling are key,
and must be correlated with clinical data. Until this relationship is more fully understood it is
not clear if novel translational approaches targeting the pathways of apoptosis would improve
immune mediated viral clearance or aid in viral replication and dissemination. In conclusion,
our study of leucocytes in patients with CCHF provides further evidence of apoptosis in the
disease and suggests dominant extrinsic pathway activation, mostly related with TNF family
members, but additional intrinsic pathway activation in severe/fatal cases.
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